Estradiol/progesterone - TherapeuticsMD

Drug Profile

Estradiol/progesterone - TherapeuticsMD

Alternative Names: 17β-estradiol/progesterone -TherapeuticsMD; Progesterone/estradiol - TherapeuticsMD; TX 12-001-HR; TX-001HR; TX-006HR; TX-008HR

Latest Information Update: 11 Apr 2017

Price : $50

At a glance

  • Originator TherapeuticsMD
  • Class Estradiol congeners; Estrenes; Hormonal replacements; Pregnenediones
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Endometrial hyperplasia; Menopausal syndrome

Most Recent Events

  • 03 Apr 2017 Updated efficacy data from the phase III REPLENISH trial in Menopausal syndrome released by TherapeuticsMD
  • 01 Mar 2017 TherapeuticsMD plans a phase I trial for Endometrial hyperplasia (Topical) in USA (TherapeuticsMD 10-K, March 2017)
  • 28 Feb 2017 TherapeuticsMD has pending patent applications for Estradiol/progesterone combination in Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea (TherapeuticsMD 10-K, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top